特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
359823

リゾホスファチジン酸受容体1:パイプライン分析

Lysophosphatidic Acid Receptor 1 - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 35 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.56円
リゾホスファチジン酸受容体1:パイプライン分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 35 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、リゾホスファチジン酸受容体1を標的とする薬剤の適応症、開発段階、作用機序、投与経路および分子タイプ別の分析、薬剤の薬理作用に関する記述、これまでの研究開発動向、最新のニュースや発表、薬剤の開発に従事している主な企業の概要、休止/中止されたプロジェクトの情報などをお届けします。

イントロダクション

  • 調査範囲

リゾホスファチジン酸受容体1の概要

治療薬の開発

リゾホスファチジン酸受容体1:開発中の製品 - 開発段階別

リゾホスファチジン酸受容体1:開発中の製品 - 治療範囲別

リゾホスファチジン酸受容体1:開発中の製品 - 適応症別

リゾホスファチジン酸受容体1:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

リゾホスファチジン酸受容体1:企業で開発中の製品

リゾホスファチジン酸受容体1:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

リゾホスファチジン酸受容体1の治療薬開発に従事している企業

  • AdAlta Pty Ltd.
  • Bristol-Myers Squibb Company
  • Epigen Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • RxBio, Inc.
  • Sanofi

薬剤プロファイル

リゾホスファチジン酸受容体1:休止中のプロジェクト

リゾホスファチジン酸受容体1:主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Curadim Pharma Co Ltd, H1 2020
  • Pipeline by Horizon Therapeutics PLC, H1 2020
  • Pipeline by Novo Nordisk AS, H1 2020
  • Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Pipeline by RxBio Inc, H1 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
目次
Product Code: GMDHC2362TDB

Summary:

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 9 molecules.The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 1 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Metabolic Disorders, Genito Urinary System And Sex Hormones, Immunology, Male Health, Musculoskeletal Disorders, Oncology and Toxicology which include indications Diabetic Nephropathy, Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Pulmonary Fibrosis, Benign Prostatic Hyperplasia, Diarrhea, Fibrosis, Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Systemic Sclerosis (Scleroderma) and Triple-Negative Breast Cancer (TNBC).

The latest report Lysophosphatidic Acid Receptor 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Co
  • Curadim Pharma Co Ltd
  • Horizon Therapeutics PLC
  • Novo Nordisk AS
  • Ono Pharmaceutical Co Ltd
  • RxBio Inc
  • Takeda Pharmaceutical Co Ltd
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
  • BMS-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-986278 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CP-2090 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EPGN-696 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HZN-825 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-7300243 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rx-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize LPA1 for Pulmonary Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-615 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Discontinued Products
  • Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.